Online Only Articles

Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study

Department of Hematology, Karolinska University Hospital, Stockholm, Sweden
GlaxoSmithKline, Research Triangle Park, NC, USA
Cancer Therapy Research Center, San Antonio, TX, USA (formerly Roswell Park Cancer Institute, Buffalo, NY, USA)
UCSD Moores Cancer Center, La Jolla, CA, USA
Faculty Hospital Brno, Dept of Internal Medicine/Hemato-Oncology, Czech Republic
Universitätsklinikum Ulm, Department of Internal Medicine III, Germany
Center for Clinical Haematology, Nottingham University Hospitals, UK
Department of Hematology, Medical University of Gdansk, Poland
Weill Cornell Medical College, Division of Hematology/Oncology, New York, NY, USA
Department of Hematology, Medical University of Lodz, Poland
St James’ Institute of Oncology, St James’ University Hospital, Leeds, UK
First Faculty of Medicine, Charles University General Hospital, Prague, Czech Republic
The Ernest and Helen Scott Haematological Research Institute, University of Leicester, UK
Klinika Hematologii CMUJ, Krakow, Poland
University Hospital Kralovske Vinohrady, Department of Clinical Hematology, Prague, Czech Republic
GlaxoSmithKline, Collegeville, PA, USA
GlaxoSmithKline, Collegeville, PA, USA
GlaxoSmithKline, Research Triangle Park, NC, USA
GlaxoSmithKline, Research Triangle Park, NC, USA
Genmab, Copenhagen, Denmark
Genmab, Copenhagen, Denmark
The University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA
Vol. 100 No. 8 (2015): August, 2015 https://doi.org/10.3324/haematol.2014.121459